Radiogenomics: the promise of personalized treatment in radiation oncology?

Significant variability exists in normal tissue reactions in patients with cancer receiving radiotherapy, with a subpopulation exhibiting increased toxicity to ionizing radiation. Genomic studies have proposed that single nucleotide polymorphisms in DNA repair genes, cytokines, and reactive oxygen species may play a role in clinical radiosensitivity. Additional research examining the association between genetic variants and radiation-induced inflammation and fibrosis may spur the development of targeted therapy in radiation oncology, which could increase cure rates and limit toxicity. As more people become long-term cancer survivors, oncology nurses must aggressively assess and manage late treatment side effects to optimize patient functioning and quality of life. The purpose of the current article is to describe the effect of ionizing radiation on normal and irradiated tissue, discuss genetic mutations that are proposed to influence radiosensitivity, and identify future areas of research on the association between genetics and radiation toxicity.

[1]  F. B. Sørensen,et al.  Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATMndash; a study based on DNA from formalin fixed paraffin embedded tissue samples , 2006, International journal of radiation biology.

[2]  D. Boreham,et al.  Radiation-induced lymphocyte apoptosis to predict radiation therapy late toxicity in prostate cancer patients. , 2009, International journal of radiation oncology, biology, physics.

[3]  S. Gotoff,et al.  Ataxia Telangiectasia: Neoplasia, Untoward Response to X -Irradiation, and Tuberous Sclerosis , 1967 .

[4]  R. Stock,et al.  ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[5]  D. DavidS.ShimmM..  Perez and Brady's Principles and Practice of Radiation Oncology , 2008 .

[6]  T. Dörk,et al.  ATM missense variant P1054R predisposes to prostate cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  R. Shaw,et al.  Osteoradionecrosis in head-and-neck cancer has a distinct genotype-dependent cause. , 2012, International journal of radiation oncology, biology, physics.

[8]  J. Overgaard,et al.  Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  J. Overgaard,et al.  Does variability in normal tissue reactions after radiotherapy have a genetic basis--where and how to look for it? , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Alison M. Dunning,et al.  Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype , 2009, Nature Reviews Cancer.

[11]  R. Stock,et al.  Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[12]  R. Mirimanoff,et al.  CD4 and CD8 T-Lymphocyte Apoptosis Can Predict Radiation-Induced Late Toxicity: A Prospective Study in 399 Patients , 2005, Clinical Cancer Research.

[13]  R. Porcher,et al.  Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Daniel Gomez,et al.  Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Cha Soon Kim,et al.  Intrinsic radiosensitivity correlated with radiation-induced ROS and cell cycle regulation , 2010, Molecular & Cellular Toxicology.

[16]  R. Stock,et al.  ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. , 2002, International journal of radiation oncology, biology, physics.

[17]  R. Gatti.  The Inherited Basis of Human Radiosensitivity , 2001, Acta oncologica.

[18]  C. Andreassen.  Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? , 2005, Acta oncologica.

[19]  T. Dörk,et al.  Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  A. Dunning,et al.  Genome-wide association studies and prediction of normal tissue toxicity. , 2012, Seminars in radiation oncology.

[21]  J. Yarnold,et al.  TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  J. Overgaard,et al.  Genetic markers for prediction of normal tissue toxicity after radiotherapy. , 2008, Seminars in radiation oncology.

[23]  Petra Seibold,et al.  Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  M. Martin,et al.  TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? , 2000, International journal of radiation oncology, biology, physics.

[25]  L. Livi,et al.  Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  M. Fernet,et al.  Predictive markers for normal tissue reactions: fantasy or reality? , 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[27]  Andrew Leask,et al.  TGF‐β signaling and the fibrotic response , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  W. Gradishar,et al.  American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Sambasivarao Damaraju,et al.  Association of DNA Repair and Steroid Metabolism Gene Polymorphisms with Clinical Late Toxicity in Patients Treated with Conformal Radiotherapy for Prostate Cancer , 2006, Clinical Cancer Research.

[30]  N. Al-Rajhi,et al.  Association between Normal Tissue Complications after Radiotherapy and Polymorphic Variations in TGFB1 and XRCC1 Genes , 2010, Radiation research.

[31]  D. Brenner,et al.  A preliminary report: frequency of A-T heterozygotes among prostate cancer patients with severe late responses to radiation therapy. , 1998, The cancer journal from Scientific American.

[32]  J. Chang-Claude,et al.  Polymorphisms in Genes Related to Oxidative Stress (CAT, MnSOD, MPO, and eNOS) and Acute Toxicities from Radiation Therapy following Lumpectomy for Breast Cancer , 2006, Clinical Cancer Research.

[33]  M. Swift.  Ionizing radiation, breast cancer, and ataxia-telangiectasia. , 1994, Journal of the National Cancer Institute.

[34]  M. Martel,et al.  Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Chang-Claude,et al.  Genetic variation in normal tissue toxicity induced by ionizing radiation. , 2009, Mutation research.

[36]  J. Yarnold,et al.  Pathogenetic mechanisms in radiation fibrosis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  H. Thierens,et al.  Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. , 2009, International journal of radiation oncology, biology, physics.

[38]  S. Rogers,et al.  Genomic determinants of normal tissue toxicity after radiotherapy for head and neck malignancy: a systematic review. , 2012, Oral oncology.

[39]  D. Murray,et al.  Single nucleotide polymorphisms of DNA repair genes as predictors of radioresponse. , 2010, Seminars in radiation oncology.

[40]  B. Rosenstein.  Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. , 2011, Pharmacogenomics.

[41]  P. Lara,et al.  Prediction of normal tissue toxicity as part of the individualized treatment with radiotherapy in oncology patients. , 2012, Surgical oncology.

[42]  Christian Nicolaj Andreassena,et al.  TGFB 1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer , 2005 .

[43]  H. Thierens,et al.  TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. , 2006, International journal of radiation oncology, biology, physics.